Journey Medical Corporation
DERMDrugs in Pipeline
6
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
13dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
DERM Earnings Report
EPS Est: $-0.01 | FQ end 2026-06
How DERM's past catalysts played out
Doxycycline
Papulopustular Rosacea
Glycopyrronium Topical Wipes
Hyperhidrosis
DFD-29
Papulopustular Rosacea
Dose 1 of glycopyrrolate, 2.0% QD
Hyperhidrosis
glycopyrrolate, 1.0%
Hyperhidrosis
Glycopyrronium cloth, 2.4%
Palmar Hyperhidrosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Doxycycline | Phase 3 | Papulopustular Rosacea | - | - |
Glycopyrronium Topical Wipes | Phase 3 | Hyperhidrosis | - | - |
DFD-29 | Phase 3 | Papulopustular Rosacea | - | - |
Dose 1 of glycopyrrolate, 2.0% QD | Phase 2 | Hyperhidrosis | - | - |
glycopyrrolate, 1.0% | Phase 2 | Hyperhidrosis | - | - |
Glycopyrronium cloth, 2.4% | Phase 2 | Palmar Hyperhidrosis | - | - |
Hyperhidrosis
3 drugs in this indication
Papulopustular Rosacea
2 drugs in this indication
Palmar Hyperhidrosis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Journey Medical Corporation's drug pipeline?→
CatalystAlert tracks 6 drug candidates in Journey Medical Corporation's (DERM) pipeline across Phase 3, Phase 2. Its lead program is Doxycycline (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Journey Medical Corporation's next FDA catalyst?→
Journey Medical Corporation's (DERM) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DERM biotech catalysts?→
Add DERM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Journey Medical Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.